New treatment approach for HIV by targeting a specific protein for degradation
Targeted Degradation of HIV Integrase as a Novel Treatment of Infection
This study is exploring a new way to treat HIV by using existing medications to help the body get rid of a key protein that the virus needs to multiply, aiming to offer better options for people with drug-resistant HIV.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Xavier University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project ID | NIH-10953006 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for HIV by using a technique called proteolysis-targeting chimeras (PROTACs). Instead of creating new drugs to combat drug-resistant HIV, the study aims to utilize existing anti-HIV medications to promote the degradation of the HIV integrase protein, which is crucial for the virus's replication. By targeting this protein for destruction, the research hopes to provide a more effective treatment option for patients with drug-resistant strains of HIV. The approach involves creating small molecules that can bind to both the target protein and an E3 ubiquitin ligase, facilitating the removal of the harmful protein from the body.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who have developed resistance to current antiretroviral therapies.
Not a fit: Patients who are newly diagnosed with HIV and have not yet developed drug resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment option for patients with drug-resistant HIV infections.
How similar studies have performed: While the use of PROTACs is a relatively novel approach in HIV treatment, similar strategies have shown promise in other areas of medicine, indicating potential for success.
Where this research is happening
New Orleans, United States
- Xavier University of Louisiana — New Orleans, United States (Active)
Researchers
- Principal investigator: Wang, Guangdi — Xavier University of Louisiana
- Study coordinator: Wang, Guangdi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.